Most researchers searching for CJC-1295 in Tār soon discover that local retail options are essentially nonexistent. This matters because CJC-1295 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to material with significant impurity issues — and the vendor is the entire quality system. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. The sections below cover what Tār researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Tār researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can tell whether a COA is complete and credible. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. For Tār researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before committing to research quantities is what experienced peptide researchers consistently do. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Tār
COA-verified · International tracking · Research grade
All use of CJC-1295 in Tār or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; do not freeze and thaw reconstituted CJC-1295 multiple times by dividing into single-dose aliquots before freezing. Bacterial endotoxin contamination is the greatest safety hazard specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers combining CJC-1295 with other compounds should check the research literature for any reported interactions before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
